Article
13 Apr 2026
A Tough Dose: 100% Tariffs Target Foreign-Manufactured Brand-Name Pharmaceuticals
RANKINGS
This author falls within the Top 20% for their listed topics and industry categories. Based on Mondaq users readership, this author is ranked as VERY POPULAR in United States
AUTHORS CONTENT
Article
24 Mar 2026
Unintended Consequences: GAO Report Questions Impact Of Exercising March-In Rights For Drug Pricing
Article
12 Feb 2026
HHS Signals Policy Direction To Accelerate Adoption Of AI In Clinical Care
Article
06 Jan 2026
CMS Proposes MFN Drug Pricing Strategy For Mandatory GLOBE And GUARD Models
Article
23 Dec 2025
FDA Drives Digital Health Forward With Pilot Program For Chronic Condition Devices
Article
17 Dec 2025
Most Favored Nation Drug Pricing And Manufacturer Agreements
Article
17 Dec 2025
The Current Legal Landscape Of The 340B Drug Pricing Program
Article
17 Dec 2025
FDA's Support For Onshoring Drug Manufacturing And Increasing Oversight Of Foreign Facilities
Article
09 Dec 2025
FDA's Biosimilar Playbook: Merging Biosimilarity With Interchangeability
Article
06 Nov 2025
FDA Proposes To Remove Comparative Efficacy Studies To Accelerate Biosimilar Development
Article
18 Aug 2025
HHS Pilot Program To Evaluate 340B Drug Pricing Program Rebate Models